3-methylaminobut-2-enoic acid methyl ester | 13412-12-9

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-methylaminobut-2-enoic acid methyl ester
• 英文别名: methyl 3-(methylamino)but-2-enoate；methyl 3-methylaminocrotonate；β-Methylamino-crotonsaeure-methylester
• CAS: 13412-12-9
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: QAKYFFYZPIPLDN-UHFFFAOYSA-N

物化性质

• 熔点：
  62-68 °C
• 沸点：
  187.5±23.0 °C(Predicted)
• 密度：
  0.969±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  在常温常压下保持稳定，需避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  常温密闭保存，阴凉通风干燥。

SDS

Name:	Methyl 3-Methylaminocrotonate Material Safety Data Sheet
Synonym:	None Known
CAS:	13412-12-9

Section 1 - Chemical Product MSDS Name:Methyl 3-Methylaminocrotonate Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
13412-12-9	Methyl 3-Methylaminocrotonate	ca. 100	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Will burn if involved in a fire. Combustible solid.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Keep away from sources of ignition. Store in a cool, dry place.
Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 13412-12-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 60 - 63 deg C
Autoignition Temperature: Not available.
Flash Point: 91 deg C ( 195.80 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H11NO2
Molecular Weight: 129.16

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents, acids, bases, reducing agents.
Hazardous Decomposition Products:
Hydrogen chloride, hydrogen cyanide, carbon monoxide, oxides of nitrogen, carbon dioxide, nitric acid.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 13412-12-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 3-Methylaminocrotonate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 13412-12-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 13412-12-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 13412-12-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-methylaminobut-2-enoic acid methyl ester 在 盐酸 、 tin 、 lithium aluminium tetrahydride 、 硝酸 、 溶剂黄146 、 potassium hydroxide 作用下， 以 四氢呋喃 、 硝基甲烷 、 乙醇 、 水 、 二甲基亚砜 为溶剂， 反应 30.5h， 生成 3-(hydroxymethyl)-5-methoxy-1,2-dimethyl-1H-indole-4,7-dione
  参考文献：
  名称：

  Bexarotene prodrugs: Targeting through cleavage by NQO1 (DT-diaphorase)

  摘要：

  Bexarotene, a retinoid X receptor (RXR) agonist, is being tested as a potential disease modifying treatment for neurodegenerative conditions. To limit the peripheral exposure of bexarotene and release it only in the affected areas of the brain, we designed a prodrug strategy based on the enzyme NAD( P) H/quinone oxidoreductase (NQO1) that is elevated in neurodegenerative diseases. A series of indolequinones (known substrates of NQO1) was synthesized and coupled to bexarotene. Bexarotene-3(hydroxymethyl)-5-methoxy-1,2-dimethyl-1H-indole-4,7-dione ester 7a was cleaved best by NQO1. The prodrugs are not cleaved by esterase. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.003
• 作为产物：
  描述：

  β-Azidoisovaleriansaeuremethylester 生成 3-methylaminobut-2-enoic acid methyl ester
  参考文献：
  名称：

  Photochemische Untersuchungen an vicinal-substituierten terti�ren Alkylaziden

  摘要：

  DOI：

  10.1007/bf00911163

文献信息

• Synthesis and some transformations of 1-chloro-2,2,2-trifluoroethyl isocyanate
  作者：Petro P. Onys’ko、Olena I. Kyselyova、Kateryna A. Zamulko、Oleksandr O. Shalimov、Sergiy M. Kurilchyk

  DOI：10.1016/j.jfluchem.2015.01.020

  日期：2015.5

  A convenient synthetic approach for previously unknown 1-chloro-2,2,2-trifluoroethyl isocyanate, based on reaction of easily accessible N-(2,2,2-trifluoroethyl-1-hydroxy)-O-ethylcarbamate with thionyl chloride and/or phosphorus pentachloride, was developed. The synthetic potential of the isocyanate as novel bielectrophilic building block was demonstrated by its easy functionalization with N- and O-centered

  一种基于未知的N-（2,2,2-三氟乙基-1-羟基）-O-乙基氨基甲酸酯与亚硫酰氯和/或二甲基亚砜的反应的先前未知的1-氯-2,2,2-三氟乙基异氰酸酯的便捷合成方法或开发了五氯化磷。异氰酸酯作为新型双亲电子结构单元的合成潜力已通过其易于被N-和O-中心亲核试剂官能化（涉及C N C三联体的一个或两个亲电子中心参与）而得到证明。
• POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：CLARK Ryan

  公开号：US20110082164A1

  公开（公告）日：2011-04-07

  Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

  本文描述了一些作为赖氨酸磷脂酸受体拮抗剂的化合物。还描述了包括本文描述的化合物的药物组合物和药物，以及使用这些拮抗剂的方法，单独或与其他化合物结合，用于治疗依赖或介导赖氨酸磷脂酸的疾病或病症。
• An efficient synthesis of multisubstituted 4-nitrobuta-1,3-dien-1-amines and application in cyclisation reactions
  作者：Brigita Vigante、Aiva Plotniece、Martins Rucins、Marina Petrova、Ruslan Muhamadejev、Karlis Pajuste、Sergey Belyakov、Yuriy G. Shermolovich、Arkadij Sobolev

  DOI：10.1016/j.tet.2018.03.075

  日期：2018.5

  synthetic usefulness of obtained 4-nitrobuta-1,3-dien-1-amines has also been demonstrated by achieving the synthesis of multisubstituted 5-nitro-1,6-dihydropyridines in two-component cyclocondensation reactions of 4-nitrobuta-1,3-dien-1-amines with aromatic or aliphatic aldehydes. Lastly, diverse N-H and N-substituted 5-nitro-1,6-dihydropyridines have been obtained in 35–87% yields.

  由3-氨基巴豆酸酯和硝基乙醛钾盐合成多取代的4-nitrobuta-1,3-dien-1-amines（nitrodienamines）的产率为45-89％。这一一步方案可与各种NH和N-取代的3-氨基巴豆酸酯有效结合，并同时提供伯氮和仲氮二烯胺。另外，已经显示了4-硝基丁-1，3-二烯-1-胺的2和3位上的取代基的可能变化。通常，仲4-硝基丁-1,3-dien-1-胺的收率低于伯。通过在4-硝基丁-1的两组分环缩合反应中实现多取代的5-硝基-1,6-二氢吡啶的合成，也证明了所获得的4-硝基buta-1,3-dien-1-胺的合成有用性。 3-dien-1-胺与芳族或脂族醛。
• [EN] COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS ET PROCÉDÉS D'UTILISATION
  申请人：EXELIXIS INC

  公开号：WO2021173591A1

  公开（公告）日：2021-09-02

  The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

  本公开涉及一般与化合物和药物组合物相关的内容，这些化合物和药物组合物适用作为蛋白激酶的调节剂，并且适用于治疗至少部分由蛋白激酶介导的疾病的方法。
• [EN] LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS D'ACIDE LYSOPHOSPHATIDIQUE
  申请人：INTERMUNE INC

  公开号：WO2013025733A1

  公开（公告）日：2013-02-21

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  提供了化合物、制备这种化合物的方法、包含这种化合物的药物组合物和药物，以及使用这种化合物治疗、预防或诊断与一种或多种赖氨酸磷脂酸受体相关的疾病、紊乱或状况的方法。